KORU Medical Systems (NASDAQ:KRMD) Stock Rating Upgraded by Wall Street Zen

KORU Medical Systems (NASDAQ:KRMD) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Other equities research analysts have also issued research reports about the company. Weiss Ratings raised KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. B. Riley Financial upped their target price on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $6.00 price target on shares of KORU Medical Systems in a report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, KORU Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

KORU Medical Systems Price Performance

KRMD opened at $4.49 on Friday. The company has a fifty day moving average price of $4.07 and a 200-day moving average price of $4.67. The firm has a market capitalization of $206.23 million, a P/E ratio of -89.80 and a beta of 0.41. KORU Medical Systems has a one year low of $2.91 and a one year high of $6.61.

Insider Buying and Selling

In related news, insider Adam R. Kalbermatten purchased 12,500 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $3.94 per share, with a total value of $49,250.00. Following the purchase, the insider directly owned 312,500 shares in the company, valued at approximately $1,231,250. This represents a 4.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have purchased 28,000 shares of company stock valued at $109,430. 18.50% of the stock is owned by insiders.

Institutional Trading of KORU Medical Systems

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its position in KORU Medical Systems by 52.1% in the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after acquiring an additional 3,478 shares in the last quarter. Lazard Asset Management LLC bought a new position in KORU Medical Systems in the second quarter valued at $59,000. Acadian Asset Management LLC purchased a new stake in KORU Medical Systems during the first quarter valued at about $63,000. Arrowstreet Capital Limited Partnership purchased a new stake in KORU Medical Systems during the first quarter valued at about $79,000. Finally, Invesco Ltd. bought a new stake in KORU Medical Systems during the second quarter worth about $80,000. 58.60% of the stock is owned by institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.